

**Table S1. Power for Primary Endpoint in INVEST-GENES**

MAF	Mode	RR	Alpha	Alpha
			<b>0.05</b>	<b>0.007</b>
<b>Predicted Power</b>				
0.1	A	1.25	0.30	0.10
	A	1.50	0.76	0.47
	A	>1.75	<b>0.97</b>	<b>0.85</b>
0.2	A	1.25	0.47	0.20
	A	1.50	<b>0.92</b>	0.75
	A	>1.75	<b>0.99</b>	<b>0.97</b>
0.3	A	1.25	0.55	0.27
	A	1.50	<b>0.96</b>	<b>0.83</b>
	A	>1.75	<b>0.99</b>	<b>0.99</b>
0.4	A	1.25	0.59	0.30
	A	1.50	<b>0.96</b>	<b>0.85</b>
	A	>1.75	<b>0.99</b>	<b>0.99</b>
0.1	D	1.25	0.25	0.08
	D	1.50	0.68	0.38
	D	>1.75	<b>0.93</b>	0.75
0.2	D	1.25	0.33	0.12
	D	1.50	0.79	0.52
	D	>1.75	<b>0.97</b>	<b>0.87</b>
0.3	D	1.25	0.32	0.11
	D	1.50	0.76	0.49
	D	>1.75	<b>0.95</b>	<b>0.82</b>
0.4	D	1.25	0.27	0.09
	D	1.50	0.66	0.37
	D	>1.75	<b>0.89</b>	0.68

MAF, minor allele frequency; A, additive mode of inheritance; D, dominant mode of inheritance, RR, relative risk.

Table S2. LXRA gene (*NRIH3*) Diplotypes frequencies in INVEST-GENES case control data set

<b>Diplotype</b>	<b>rs11039149 (A&gt;G)</b>	<b>Diplotype frequency</b>
	<b>rs12221497 (G&gt;A)</b>	<b>N (%)</b>
	<b>rs2279238 (C&gt;T)</b>	
D1	AGC/AGC	231 (21.8)
D2	AGC/AGT	206 (19.5)
D3	AGC/GGC	203 (19.2)
D4	AGC/AAC	104 (9.8)
D5	AGT/GGC	86 (8.1)
D6	AAC/GGC	65 (6.1)
D7	GGC/GGC	62(5.9)
D8	AGT/AGT	60 (5.7)
D9	AGT/AAC	34 (3.2)
D10	AGT/AGC	3 (<1)
D11	AAC/AAC	2 (<1)
D12	AGC/GAC	1 (<1)
D13	AGT/GGT	1 (<1)
D14	AGT/AAT	1(<1)

Figure S1. Adjusted odds ratios for primary outcome based on common diplotypes in Non-Blacks




Figure S1. The reference diplotype is D1, which contains wild type alleles for the three independently significant SNPs (See Table S1). Primary outcomes are a composite of the first occurrence of all-cause death, nonfatal MI or nonfatal stroke. Odds Ratios (OR) from logistic regression adjusted for: age, sex, race/ethnicity, BMI, INVEST treatment strategy, history of CHF, history of MI and history of diabetes at baseline.